Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 27 - Drugs for disorders of the senses
Patents for A61P 27 - Drugs for disorders of the senses (53,017)
09/2003
09/25/2003WO2003070738A3 Topiramate salts and compositions comprising and methods of making and using the same
09/25/2003WO2003068171A3 Method and composition for treatment of inflammation and aids-associated neurological disorders
09/25/2003WO2003039472A3 Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process
09/25/2003WO2003020219A3 Aerosolized decongestants for the treatment of sinusitis
09/25/2003WO2003013530A3 Salts of substituted 1, 2, 3, 4-tetrahydroquinoline-2-carboxylic acid derivatives as nmda antagonists
09/25/2003WO2003011249A3 Ophthalmic composition containing n-acetylcysteine for the treat ment of dry-eye syndrome
09/25/2003WO2003002108A3 Use of tyrosine kinase inhibitors for treating inflammatory diseases
09/25/2003WO2002100436A3 Ophthalmic once-a-day composition
09/25/2003WO2002074733A3 Tryptase-inhibitors
09/25/2003WO2002064634A3 Human monoclonal antibodies to fc alpha receptor (cd89)
09/25/2003US20030181507 Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators
09/25/2003US20030181481 Therapeutic drugs for treating central nervous system disorders
09/25/2003US20030181477 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
09/25/2003US20030181476 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereof
09/25/2003US20030181464 Phenylsulphonylipiperazinyl derivatives as 5-ht receptor ligands
09/25/2003US20030181443 Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof
09/25/2003US20030181441 Tumor necrosis factor-alpha converting enzyme antagonists, such as (2S,3S)-4-(4-(3,5-difluro-benzyloxy)-benzenesulfonyl) -2-methyl-thiomorpholine-3-carboxylic acid hydroxyamide, used as antiarthritic or anticarcinogenic agents
09/25/2003US20030181388 Formula I are potent inhibitors of caspases and apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire
09/25/2003US20030180934 Plasminogen-like polynucleotides, polypeptides, and antibodies
09/25/2003US20030180357 Core with coating; water soluble dye in matrix as core; gellan gum coatings; easier detection of tablet
09/25/2003US20030180317 Diagnosis ear infections in children
09/25/2003US20030180300 Collagen biosynthesis; controlling cell differentiation, cell proliferation
09/25/2003US20030180294 Administering vascular endothelial growth factor receptor inhibitor; supression lymphangiogenesis
09/25/2003US20030180288 Methods and compositions for modulating immune response and for the treatment of inflammatory disease
09/25/2003US20030180225 Walnut and ryegrass allergens
09/25/2003US20030180224 Photosensitisers
09/25/2003CA2479222A1 Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
09/25/2003CA2479141A1 Pyridone derivatives
09/25/2003CA2479118A1 Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
09/25/2003CA2478997A1 Use of copper chelating tetraamines for the treatment of cardiovascular disease and heart failure
09/25/2003CA2478965A1 Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
09/25/2003CA2478795A1 Use of rapamycin for inhibiting cell death
09/25/2003CA2478653A1 Methods of treatment with selective ep4 receptor agonists
09/25/2003CA2476908A1 Composition comprising an l-ascorbic acid and an organic base for treatment of ocular disorders
09/24/2003EP1346993A1 Lactam compounds and medicinal use thereof
09/24/2003EP1346982A1 Vla-4 inhibitors
09/24/2003EP1346730A1 Pretargeting methods and novel pretargeting conjugates
09/24/2003EP1346728A1 Ophthalmological preparations
09/24/2003EP1346056A1 Methods for the production of multimeric proteins, and related compositions
09/24/2003EP1346031A2 Isolated human dehydrogenases, nucleic acid molecules encoding them, and uses thereof
09/24/2003EP1345938A1 Tricyclic crf receptor antagonists
09/24/2003EP1345935A2 Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists
09/24/2003EP1345933A2 Process for making substituted 8-arylquinolinium benzenesulfonate
09/24/2003EP1345920A1 Novel sulfamides and their use as endothelin receptor antagonists
09/24/2003EP1345910A1 Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof
09/24/2003EP1345626A2 Novel pharmaceutical compositions based on anticholinergic agents and dopamine agonists
09/24/2003EP1345616A2 Reducing cellular damage in the human body
09/24/2003EP1345609A1 Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mglur 1 antagonists
09/24/2003EP1345607A1 Therapeutic combination of amlodipine and benazepril / benazeprilat
09/24/2003EP1345606A2 Texaphyrin coordination compounds and uses thereof
09/24/2003EP1345603A1 (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents
09/24/2003EP1345588A2 Sustained release drug delivery devices
09/24/2003EP1272489B1 Process for preparing crystalline form i of cabergoline
09/24/2003EP1268482B1 Pyranoindoles for treating glaucoma
09/24/2003EP1200079B1 2-aminotetralin derivatives for the therapy of glaucoma
09/24/2003EP1100480B1 Muscarinic antagonists in the treatment of presbyopia
09/24/2003EP0984959B1 Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
09/24/2003EP0944618B1 Novel n-benzenesulphonyl-l-proline derivatives, method for preparing and therapeutic use
09/24/2003EP0736022B1 5-(2-imidazolinylamino)benzimidazole derivatives, their preparation and their use as alpha-2 adrenoceptor agonists
09/24/2003CN1444589A 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
09/24/2003CN1444587A Dihydropyridine soft drug and related to composition and method
09/24/2003CN1444570A Non-steroidal inflammation inhibitors
09/24/2003CN1444566A Imidazolyl derivatives
09/24/2003CN1444558A Novel N-(2-phenyl-3-aminopropyl) naphtamides
09/24/2003CN1443763A Internediate for preparing quinoxaline diketone
09/24/2003CN1443756A Bicyclic aromatic compound
09/24/2003CN1122022C Substituted oximes as neurokinin antagonists
09/23/2003US6624199 Prophylaxis and treatment of acne and acne related skin diseases with aminobenzophenones, and novel compounds effective in the treatment, as well as pharmaceutical preparations containing these compounds and dosage units
09/23/2003US6624193 Preventive and therapeutic agents for eye diseases
09/23/2003US6624188 Method of treatment with compounds having retinoid-like activity and reduced skin toxicity and lacking teratogenic effects
09/23/2003US6624186 Modulators of SKCa, IKCa and BKCa channels.
09/23/2003US6624178 Novel compounds of the pyridinium series useful for the management of diabetes and aging-related vascular complications, including kidney disease, nerve damage, atherosclerosis, retinopathy, dermatological disorders and
09/23/2003US6624177 Treating diseases in which matrix melatoproteinases are involved such as multiple sclerosis, atherosclerotic plaque rupture, restenosis, aortic aneurism, heart failure, periodontal disease, corneal ulceration, burns, decubital
09/23/2003US6624176 Heteroaromatic substituted amides with antagonistic activity to neurokinin 1 receptors
09/23/2003US6624174 2-amino-nicotinamide derivatives and their use as VEGF-receptor tyrosine kinase inhibitors
09/23/2003US6624164 1,3-dihydro-2H-indol-2-one derivatives, preparation method and pharmaceutical composition containing them
09/23/2003US6623767 Mixture containing honey, at least one essential oil and/or at least one essential oil derivative
09/23/2003CA2139781C Ophthalmic topical composition containing (s)-timolol hemihydrate
09/18/2003WO2003076638A1 Angiogenesis inhibitors
09/18/2003WO2003076475A1 Ester derivatives of hyaluronic acid for the preparation of hydrogel materials by photocuring
09/18/2003WO2003076447A1 An optically acitve pyridine derivative and a medicament containing the same
09/18/2003WO2003076443A1 Spiro compounds with npy antagonistic activity
09/18/2003WO2003076438A1 Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase
09/18/2003WO2003076436A1 Derivatives of 4- (imidazol-5-yl)-2-(4-sulfoanilino) pyrimidine with cdk inhibitory activity
09/18/2003WO2003076435A1 Pyrimidine compounds
09/18/2003WO2003076433A1 Pyrimidine compounds
09/18/2003WO2003076430A1 Amino-derivatives as novel inhibitors of histone deacetylase
09/18/2003WO2003076427A1 Quinazoline compounds useful in therapy
09/18/2003WO2003076424A1 Macrocyclic compounds useful as pharmaceuticals
09/18/2003WO2003076421A1 Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
09/18/2003WO2003076414A2 Aryl substituted pyrimidines and the use thereof
09/18/2003WO2003076407A1 Novel chalcone derivatives and uses thereof
09/18/2003WO2003076406A1 Nitrosodiphenylamine derivatives and their pharmaceutical use against oxidative stress pathologies
09/18/2003WO2003076400A1 New inhibitors of histone deacetylase
09/18/2003WO2003076397A1 Aminoalcohol derivatives as beta-3 adrenergic receptor agonists
09/18/2003WO2003076393A1 Salts of nateglinide
09/18/2003WO2003075931A1 A method of treating diabetes mellitus including conditions associated with diabetes mellitus and complications of diabetes mellitus
09/18/2003WO2003075929A1 Inhibitors of histone deacetylase
09/18/2003WO2003075923A1 Vdac regulator
09/18/2003WO2003075921A2 Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
1 ... 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 ... 531